Akili, Inc. (NASDAQ:AKLI) Short Interest Down 35.4% in April

Akili, Inc. (NASDAQ:AKLI) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 79,600 shares, a decrease of 35.4% from the March 31st total of 123,200 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 2,330,000 shares, the short-interest ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Akili stock. StoneX Group Inc. acquired a new stake in shares of Akili, Inc. (NASDAQ:AKLI) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,064,432 shares of the company’s stock, valued at approximately $518,000. StoneX Group Inc. owned approximately 1.36% of Akili at the end of the most recent quarter. Institutional investors own 53.12% of the company’s stock.

Akili Price Performance

Akili stock opened at $0.25 on Friday. Akili has a 12-month low of $0.19 and a 12-month high of $1.67. The firm has a 50 day simple moving average of $0.28 and a 200-day simple moving average of $0.36. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.09.

Akili (NASDAQ:AKLI) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.12. Akili had a negative return on equity of 76.34% and a negative net margin of 3,545.47%. The firm had revenue of $0.75 million during the quarter, compared to analyst estimates of $1.07 million. Equities analysts anticipate that Akili will post -0.53 earnings per share for the current year.

Akili Company Profile

Akili, Inc, a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.